Contact this trialFirst, we need to learn more about you.
Corticosteroid
Teclistamab vs Lenalidomide + Dexamethasone for Multiple Myeloma
Recruiting1 awardPhase 2
Denver, Colorado
This trial is testing a new drug called Teclistamab against a combination of two existing drugs, Lenalidomide and Dexamethasone, in people with high-risk smoldering multiple myeloma. The goal is to see which treatment is more effective in preventing the progression to active multiple myeloma. Teclistamab helps the immune system target cancer cells, while Lenalidomide and Dexamethasone work together to boost the immune response and reduce inflammation.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service